Clinical trials: Chikungunya Virus
Chikungunya Virus, Dengue Virus
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions.
- Trial name
- TRUE (NCT02305732)
- Testing
- INTERCEPT Platelets
- Where
- 8 sites in Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Cerus Corporation
Chikungunya Virus Infection
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
Chikungunya virus (CHIKV) has been detected in humans in the Caribbean area for the first time in November 2013 (St-Martin Island).
- Trial name
- CHIKIVIG-01 (NCT02230163)
- Testing
- anti-CHIKV hyperimmune immunoglobulins
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Chikungunya Virus Infection
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
VLA1553-322 is a multicenter, prospective, randomized, double-blind, phase 3 clinical trial evaluating VLA1553 in comparison to a comparator (Nimenrix®) for each stratum (age group).
- Trial name
- NCT07133178
- Testing
- VLA1553, Control
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], aluminum hydroxide adjuvanted).
- Trial name
- CHIKV VLP (NCT05065983)
- Testing
- CHIKV VLP, adjuvanted
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Dengue, Chikungunya Virus Infection
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Study setting: Medellin and Bello municipalities, Colombia Health condition(s) studied: Dengue, Zika and chikungunya virus infection Intervention: Deployment of Wolbachia-infected Aedes aegypti mosquitoes in Medellin and Bello.
- Conditions
- Dengue, Chikungunya Virus Infection, Zika Virus Infection
- Trial name
- WMP-COL (NCT03631719)
- Testing
- Wolbachia-carrying Ae.aegypti mosquitoes
- Where
- Colombia
- Volunteers
- 834 people
- Sponsor
- Universidad de Antioquia
Chikungunya Fever, Chikungunya Virus
Trial of an Inactivated Chikungunya Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 2.5 mcg and 8 mcg of HydroVax-005 CHIKV vaccine given intramuscularly on Day 1 and Day…
- Conditions
- Chikungunya Fever, Chikungunya Virus, Chikungunya
- Trial name
- NCT06669208
- Testing
- HydroVax-005 CHIKV
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana
In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and…
- Trial name
- CHIK-RE-VAC (NCT06928753)
- Testing
- IXCHIQ, VIMKUNYA
- Where
- 2 sites in French Guiana, Reunion
- Volunteers
- 1,505 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Arbovirus Infections, Zika
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Zika, Dengue, Chikungunya
- Trial name
- VIRIMA (NCT04619823)
- Testing
- Blood sample collection
- Where
- New Caledonia
- Volunteers
- 250 people
- Sponsor
- Institut Pasteur
Viral Vaccines, Chikungunya Fever
Chikungunya Virus Vaccine Trial in Healthy Adults
Background: Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death.
- Conditions
- Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
- Trial name
- NCT01489358
- Testing
- VRC-CHKVLP059-00-VP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Fever
A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
To evaluate the efficacy and safety of Reduning Injection in the treatment of chikungunya fever
- Trial name
- NCT07126171
- Testing
- Reduning injection, The simulant of Reduning Injection
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Active Immunisation for Chikungunya Virus Infection
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
- Trial name
- CHIKV/II-III (NCT07555392)
- Testing
- BBV87 Chikungunya vaccine
- Where
- 10 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Bharat Biotech International Limited
Chikungunya Fever
Real-World Study on Chinese Medicine for Treating Chikungunya Fever
This study aims to evaluate the effectiveness and safety of Chinese Medicine-used alone or combined with Western medicine-in treating chikungunya fever, a mosquito-borne viral disease causing fever, rash, and severe joint pain.
- Trial name
- NCT07120724
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)
MARCH is the first randomized, double-blind, placebo-controlled evaluation of the efficacy and pathologic mechanism determined by synovial biopsy of 6 months of methotrexate (n=100) versus placebo (n=50) therapy for chronic…
- Trial name
- NCT04483466
- Testing
- Methotrexate
- Where
- Colombia
- Volunteers
- 150 people
- Sponsor
- George Washington University
Dengue, Zika
Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities
Arboviral diseases such as dengue, Zika, and chikungunya, transmitted by Aedes mosquitoes, remain an important public health concern in Colombian communities.
- Conditions
- Dengue, Zika, Chikungunya, Aedes-borne Diseases
- Trial name
- DigiAedes (NCT07517731)
- Testing
- Full intervention, Partial intervention
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Chikungunya, Arthritis
Chikungunya Arthritis in the Americas
Chikungunya is a mosquito-borne viral illness that leads to chronic joint pain in approximately one half of patients. The mechanisms leading to long term arthritis in humans has not been well established.
- Trial name
- NCT02463968
- Testing
- Venipuncture for blood draw, Arthrocentesis for synovial fluid draw
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- George Washington University
Zika Virus, Dengue Virus
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Background: Zika virus is mostly passed on by the bite of an infected mosquito. It usually causes mild illness. But in pregnant women it can cause serious birth defects to the baby.
- Conditions
- Zika Virus, Dengue Virus, Chikungunya Virus Infections
- Trial name
- NCT02794181
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Chikungunya Virus Infection
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
This is an observational, non-interventional, test-negative case-control (TNCC) study to estimate the vaccine effectiveness of VLA1553 against Chikungunya virus in a real-world setting.
- Trial name
- NCT07347002
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH